GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Question] small molecule — what am I missing here — 67 comments in the full submission. View in context.
1k
c/orforglipron·submitted 2 years ago by u/bruno_dumitru

[Question] small molecule — what am I missing here

Questionbranch of 8 comments

small molecule — what am I missing here. Searched first, found three threads that contradict each other, hence the post. Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction. Went looking for independent testing on this and found essentially nothing, which…

Read the full submission and all 67 comments →

This branch

8 comments, started 2 years ago
u/freya_marchand-11 points·2 years ago

That is a phase 2 result being quoted as though the programme had reported.

replysharereportpermalink
u/sanne_delgado1 point·2 years ago

That is a phase 2 result being quoted as though the programme had reported.

Adding the standing caveat — unapproved, and research material is not for human use.

replysharereportpermalink
u/certified_referenceQC1 point·2 years ago

oral and non-peptide is the whole engineering story

replysharereportpermalink
u/chidi_yilmaz-17 points·2 years ago

the tolerability profile reads broadly similar to the class

replysharereportpermalink
u/mateusz_mensah1 point·2 years ago

the tolerability profile reads broadly similar to the class

chidi_yilmaz is right that milligram comparisons across classes tell you nothing.

replysharereportpermalink
u/tomas_lundgren1 point·2 years ago

The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.

replysharereportpermalink
u/tidy_vialdrawer_watch281 point·2 years ago

Cosigning on daily dosing. It changes the exposure profile and it changes adherence, in both directions.

replysharereportpermalink
u/tobias_molnar1 point·2 years ago

ATTAIN and ACHIEVE are the programmes to keep straight

replysharereportpermalink

← back to the whole thread

About c/orforglipron

The small-molecule oral: why a non-peptide agonist escapes the absorption problems of oral semaglutide, what the ATTAIN and ACHIEVE readouts showed, and what a pill with no refrigeration requirement would do to the entire supply conversation this site is built around.

21kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/orforglipron rules
  1. Small molecule, not a peptide. Purity discussion here is a different problem.
  2. Cite ATTAIN/ACHIEVE arms specifically when quoting numbers.
  3. Availability speculation must be flaired Speculation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.